Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
44
Frequently Asked Questions
What is Market Cap of Arbutus Biopharma Corp?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Arbutus Biopharma Corp market cap is $768.71M.
What is the 52-week high for Arbutus Biopharma Corp?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Arbutus Biopharma Corp 52 week high is $4.73 as of September 06, 2025.
What is the 52-week low for Arbutus Biopharma Corp?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Arbutus Biopharma Corp 52 week low is $2.71 as of September 06, 2025.
What is Arbutus Biopharma Corp stock price today?
Arbutus Biopharma Corp stock price today is $4.20.
What was Arbutus Biopharma Corp stock price yesterday?
Arbutus Biopharma Corp stock price yesterday was $4.01.
What is the PE ratio of Arbutus Biopharma Corp?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Arbutus Biopharma Corp’s P/E ratio is -14.03.
What is the Price-to-Book ratio of Arbutus Biopharma Corp?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Arbutus Biopharma Corp P/B ratio is 9.2614.
What is the 50-day moving average of Arbutus Biopharma Corp?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Arbutus Biopharma Corp 50-day moving average is $3.36.
How many employess does Arbutus Biopharma Corp has?
